Meeting
2021 Gastrointestinal Cancers Symposium
Angiogenesis-related factors associated with nivolumab efficacy in patients with advanced gastric cancer after refractory or intolerant to ramucirumab-based therapy.
Authors
Yuki Matsubara
Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
Yuki Matsubara , Hideaki Bando , Takatsugu Ogata , Taiko Nakazawa , Kyoko Kato , Kazuki Nozawa , Yukiya Narita , Kazunori Honda , Toshiki Masuishi , Shigenori Kadowaki , Masashi Ando , Masahiro Tajika , Kei Muro , Hiromichi Ebi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Esophageal and Gastric Cancer
Track
Esophageal and Gastric Cancer
Sub Track
Translational Research
Citation
J Clin Oncol 39, 2021 (suppl 3; abstr 234)
DOI
10.1200/JCO.2021.39.3_suppl.234
Abstract #
234
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4 year (yr) follow-up of CheckMate 649.
First Author: Kohei Shitara
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Real-world (RW) effectiveness of nivolumab plus chemotherapy (NIVO+chemo) in patients (pts) with advanced or metastatic gastric carcinoma, gastroesophageal junction carcinoma, or esophageal adenocarcinoma (GC/GEJC/EAC).
First Author: Ian Chau
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Impact of adding nivolumab to first-line chemotherapy in patients with advanced gastric cancer.
First Author: Mai Utsumi
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Real-world effectiveness of drugs newly approved in Japan on survival in patients with advanced gastric cancer.
First Author: Toru Kadono